Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,769 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,437 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,348)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04086264 | IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 218 | AbbVieINDUSTRY | 6 | Aug 14, 2025 | clinicaltrials |
| NCT02157324 | Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic Leukemia | active not recruiting | Phase 1 | 12 | Acerta Pharma BVINDUSTRY | 1 | Aug 13, 2025 | clinicaltrials |
| NCT04822766 | A Study Comparing Allogeneic Hematopoietic Cell Transplantation Versus Best Available Standard of Care Therapy in Elderly Patients With Acute Myeloid Leukemia(ALLO-BEST) | active not recruiting | N/A | 24 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT02790515 | Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation | active not recruiting | Phase 2 | 170 | St. Jude Children's Research HospitalOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT03684889 | CD19-specific CAR T Cells With a Fully Human Binding Domain for CD19+ Leukemia or Lymphoma | active not recruiting | Phase 1 | 16 | Seattle Children's HospitalOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT06944119 | Assesment of the Immune Response to RSV Vaccine in Patients With Myeloma, Lymphoma and Hematological Leukemia | active not recruiting | — | 250 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Jul 28, 2025 | clinicaltrials |
| NCT05182385 | Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) | active not recruiting | Phase 1 / Phase 2 | 30 | Goethe UniversityOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT03897127 | Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics | active not recruiting | Phase 3 | 882 | University of UlmOTHER | 2 | Jul 17, 2025 | clinicaltrials |
| NCT04159779 | A Study of Clinical Outcomes in Chronic Lymphocytic Leukemia (CLL) Patients Treated With Venetoclax in Greece | active not recruiting | — | 180 | AbbVieINDUSTRY | 1 | Jul 17, 2025 | clinicaltrials |
| NCT06220097 | Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies | active not recruiting | Phase 2 | 28 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 17, 2025 | clinicaltrials |
| NCT03971799 | Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 52 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Jul 14, 2025 | clinicaltrials |
| NCT07060612 | Incidence and Risk Factors for the Development of Invasive Fungal Infection in Patients Diagnosed With Acute Myeloblastic Leukemia (HIFA)(HIFA) | active not recruiting | — | 300 | Instituto de Investigacion Sanitaria La FeOTHER | 1 | Jul 11, 2025 | clinicaltrials |
| NCT04891757 | FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies | active not recruiting | Phase 1 | 144 | Foghorn Therapeutics Inc.INDUSTRY | 1 | Jul 10, 2025 | clinicaltrials |
| NCT04851717 | Investigation of Remimazolam in Children Undergoing Sedation for Medical Procedures | active not recruiting | Phase 2 / Phase 3 | 100 | Acacia Pharma LtdINDUSTRY | 2 | Jul 1, 2025 | clinicaltrials |
| NCT03817320 | PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma | active not recruiting | Phase 1 / Phase 2 | 24 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 2 | Jun 17, 2025 | clinicaltrials |
| NCT01985061 | Evaluation of 3 Different Doses of IV Busulfan(AAA) | active not recruiting | Phase 2 | 177 | Institut Paoli-CalmettesOTHER | 1 | Jun 15, 2025 | clinicaltrials |
| NCT04541212 | Identification and Evaluation of Patients at Risk of Developing Cardiotoxicity After Receiving Chemotherapy for Breast Cancer, Lymphoma or Leukemia(CarChem) | active not recruiting | — | 169 | Montreal Heart InstituteOTHER | 1 | Jun 15, 2025 | clinicaltrials |
| NCT05936853 | The EPigenetic Consequences in Children of Intravenous vs Volatile Anaesthesia for Surgery (EPIVA)(EPIVA) | active not recruiting | N/A | 16 | University Hospital Southampton NHS Foundation TrustOTHER | 1 | Jun 15, 2025 | clinicaltrials |
| NCT04706676 | Integrative Neuromuscular Training in Adolescents and Children Treated for Cancer(INTERACT) | active not recruiting | N/A | 132 | Rigshospitalet, DenmarkOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT04415008 | Efficacy of HAD Induction With Intensified Cytarabine in Newly-diagnosed CEBPA Double Mutated Acute Myeloid Leukemia | active not recruiting | Phase 2 | 61 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT03031262 | Efficacy and Safety of Chidamide in CBF Leukemia | active not recruiting | Phase 1 / Phase 2 | 250 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT03512405 | Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia | active not recruiting | Phase 1 / Phase 2 | 36 | City of Hope Medical CenterOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT05356169 | Intensive Therapy Combined With Venetoclax for Adult Acute Myeloid Leukemia | active not recruiting | Phase 2 / Phase 3 | 312 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT01361711 | Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia | active not recruiting | Phase 2 | 53 | Northwestern UniversityOTHER | 2 | May 23, 2025 | clinicaltrials |
| NCT04730258 | A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML(TWT-202) | active not recruiting | Phase 1 / Phase 2 | 72 | Treadwell Therapeutics, IncINDUSTRY | 3 | May 18, 2025 | clinicaltrials |
| NCT04202835 | ATG Plus PTCy vs ATG for CGVHD Prophylaxis | active not recruiting | Phase 2 | 80 | McMaster UniversityOTHER | 2 | May 11, 2025 | clinicaltrials |
| NCT05179824 | Tempus Priority Study: A Pan-tumor Observational Study | active not recruiting | — | 1,000 | Tempus AIINDUSTRY | 1 | May 6, 2025 | clinicaltrials |
| NCT04232241 | Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia | active not recruiting | Phase 2 | 167 | Universitätsklinikum Hamburg-EppendorfOTHER | 7 | Apr 22, 2025 | clinicaltrials |
| NCT02735083 | A Study to Evaluate the Long-term Safety of Patients With Advanced Lymphoid Leukemia Who Have Been Previously Administered With UCART19 | active not recruiting | Phase 1 | 28 | Institut de Recherches Internationales ServierOTHER | 5 | Apr 11, 2025 | clinicaltrials |
| NCT06918080 | Hepatoprotective Measures for Children at High Risk of NAFLD | active not recruiting | Phase 4 | 200 | Ain Shams UniversityOTHER | 1 | Apr 9, 2025 | clinicaltrials |
| NCT04233346 | The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation | active not recruiting | Phase 2 | 93 | Otsuka Beijing Research InstituteINDUSTRY | 1 | Apr 4, 2025 | clinicaltrials |
| NCT03918655 | MIF Involvement in AML(MIFAML) | active not recruiting | — | 186 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT05883956 | A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia(PREFER-HMA) | active not recruiting | Phase 3 | 13 | Otsuka Australia Pharmaceutical Pty LtdINDUSTRY | 2 | Mar 20, 2025 | clinicaltrials |
| NCT06396611 | Exercise As Intervention in Chronic Lymphocytic Leukemia(ADRENALINE) | active not recruiting | N/A | 11 | Universidade do PortoOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT03496402 | Biological Characterisation of High Risk CHildhood Cancer in Children, Adolescents and Young Adults (MICCHADO)(MICCHADO) | active not recruiting | N/A | 600 | Institut CurieOTHER | 1 | Mar 18, 2025 | clinicaltrials |
| NCT04980885 | A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 68 | AkesoINDUSTRY | 1 | Mar 3, 2025 | clinicaltrials |
| NCT04072458 | A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies | active not recruiting | Phase 1 | 30 | Bio-Path Holdings, Inc.INDUSTRY | 1 | Feb 24, 2025 | clinicaltrials |
| NCT05434312 | TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) Patients | active not recruiting | Phase 1 | 90 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | Feb 24, 2025 | clinicaltrials |
| NCT03283137 | Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL | active not recruiting | Phase 1 | 20 | University of ChicagoOTHER | 1 | Feb 7, 2025 | clinicaltrials |
| NCT06386861 | Validating the Spanish "Attitudes Toward Genomics and Precision Medicine" (AGPM). | active not recruiting | N/A | 851 | Boston CollegeOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT04722848 | Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL | active not recruiting | Phase 3 | 236 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT05885464 | A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL) | active not recruiting | Phase 1 / Phase 2 | 5 | Beam Therapeutics Inc.INDUSTRY | 1 | Jan 13, 2025 | clinicaltrials |
| NCT06764589 | Liquid Micro-biopsy: a Novel Approach to Study Tumor Microenvironment From the Peripheral Blood | active not recruiting | — | 90 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Jan 8, 2025 | clinicaltrials |
| NCT04476199 | Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) with Newly Diagnosed AML Eligible for Allo-SCT | active not recruiting | Phase 2 | 100 | Gruppo Italiano Trapianto di Midollo OsseoOTHER | 1 | Jan 6, 2025 | clinicaltrials |
| NCT04160546 | Study to Evaluate the Reinduction and Second Stop of TKI with Ponatinib in CML in Molecular Response (ResToP)(ResToP) | active not recruiting | Phase 2 | 80 | Fundacion CRIS de Investigación para Vencer el CáncerOTHER | 1 | Dec 31, 2024 | clinicaltrials |
| NCT03836261 | Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL(AMPLIFY) | active not recruiting | Phase 3 | 984 | Acerta Pharma BVINDUSTRY | 27 | Dec 27, 2024 | clinicaltrials |
| NCT04623944 | NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS | active not recruiting | Phase 1 | 61 | Nkarta, Inc.INDUSTRY | 1 | Dec 27, 2024 | clinicaltrials |
| NCT03595787 | COaching and Prehabilitation: Faisability Study in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome(COHABILIT) | active not recruiting | N/A | 50 | Institut Paoli-CalmettesOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT04027309 | A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy(HOVON 156 AML) | active not recruiting | Phase 3 | 777 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 13 | Dec 17, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Aug 14, 2025source: clinicaltrials